NASDAQ$IMNM
Immunome Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Immunome Inc reported financial results for the second quarter ended June 30, 2025, with higher collaboration revenue and increased operating expenses.
The company recognized $4.0 million in collaboration revenue during Q2 2025, up from the prior year period. Operating expenses rose, leading to a net loss of $43.4 million and EPS of $(0.50). The company maintained a strong liquidity position with $143.9 million in cash and cash equivalents.
- Collaboration revenue increased to $4.0 million for the three months ended June 30, 2025.
- R&D expenses were $40.5 million and G&A expenses were $10.0 million.
- Net loss totaled $43.4 million with basic and diluted EPS of $(0.50).
- Cash and cash equivalents stood at $143.9 million and total assets at $296.3 million at period end.
Headline financials
Revenue & EPS history
Immunome · Revenue · Quarterly
$4.02M
Revenue by segment
Immunome · $4.02M total across 1 segment · Q2 2025
- Collaboration Revenue$4.02M—100.0%
Forward guidance
The company plans to report topline data from the Phase 3 RINGSIDE trial of varegacestat in the second half of 2025 and initiate additional Phase 1 trials.
Tailwinds
- Robust cash position to fund ongoing clinical development.
- Multiple pipeline assets advancing with recent IND clearances.
Headwinds
- Continued operating losses expected as R&D investment grows.
- No product revenue anticipated until regulatory approvals are obtained.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports
+0.8%
Avg return
Earnings day
-2.4%
Avg return
5 days after
+0.6%
Avg return
30 days after
32%
7 / 22 earnings
Positive
+24.1%
Q4 2021
Best reaction
-10.8%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | -1.3% | -9.1% | -20.0% | |
| Q4 2025 | +4.7% | -1.0% | +1.4% | |
| Q3 2025 | -5.0% | +2.5% | +12.3% | |
| Q1 2025 | +1.1% | -1.0% | +15.0% | |
| Q4 2024 | -4.0% | -18.9% | -7.7% | |
| Q3 2024 | -10.8% | -24.5% | +0.7% | |
| Q2 2024 | +4.7% | +4.7% | +11.9% | |
| Q1 2024 | -1.3% | -6.2% | -3.2% | |
| Q4 2023 | -2.3% | -16.2% | -46.2% | |
| Q3 2023 | -8.1% | -8.9% | -12.2% | |
| Q2 2023 | -1.9% | -0.8% | +3.9% | |
| Q1 2023 | +2.3% | +11.9% | -6.2% | |
| Q4 2022 | +20.8% | +18.9% | +2.3% | |
| Q3 2022 | +0.0% | -27.6% | -8.5% | |
| Q2 2022 | +19.3% | +13.6% | +24.7% | |
| Q1 2022 | -2.6% | +19.6% | +46.5% | |
| Q4 2021 | +24.1% | +20.1% | -26.3% | |
| Q3 2021 | -1.0% | -5.1% | -9.3% | |
| Q2 2021 | -3.2% | -11.9% | +51.2% | |
| Q1 2021 | -10.7% | -3.0% | -2.9% | |
| Q4 2020 | -1.0% | -4.3% | -8.3% | |
| Q3 2020 | -5.5% | -6.4% | -6.1% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro